FDA PMA
FDA Class 3
30-Day Notice Accepted
🇺🇸 United States
Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System
PMA: P200010
·
Supplement: S023
·
Decision Jan 22, 2025
Classifications
1
FEI Numbers
12
Registration Numbers
12
Basic Information
- Device Name
- Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System
- Trade Name
- Guardant360 CDx
- PMA Number
- P200010
- Supplement Number
- S023
- Device Class
- FDA Class 3
- Product Code
- PQP
- Generic Name
- Next generation sequencing oncology panel, somatic or germline variant detection system
- Medical Specialty
- Unknown
- Advisory Committee
- Pathology
- Decision
- 30-Day Notice Accepted
- Decision Code
- OK30
- Decision Date
- January 22, 2025
- Date Received
- December 26, 2024
- Supplement Type
- 30-Day Notice
- Supplement Reason
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
- Expedited Review
- N
Advisory Committee Statement
approval for moving manufacturing activities within the same establishment
Classifications
This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| PQP | Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System | FDA class 3 | Unknown |